- €43.63bn
- €77.10bn
- €45.58bn
Brief: US FDA Grants Accelerated Approval To Bayer's Hyrnuo As First-Line Targeted Therapy For Patients With Her2-Mutated Non-Small Cell Lung Cancer
Brief: FDA Grants Accelerated Approval To Sevabertinib For A Type Of Non-Small Cell Lung Cancer
Brief: Bayer And Neste Close Commercial Agreement To Jointly Scale Newgold® Winter Canola For Biofuels Production
Brief: Bayer, Neste Close Commercial Agreement
Brief: Bayer Starts Phase II Study Of Atrial Fibrillation Drug Candidate
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
Bayer says Crop Science unit makes progress on product launches
Trump administration announces drug pricing deals with CSL, Astellas and others (updated)
Trump administration to announce drug pricing deals
Brief: Esc Guidelines Provide Class IA Recommendation For Finerenone For Heart Failure
Brief: Bayer Files In Japan For Expanded Kerendia Use
U.S. court dismisses appeal over objections to $7.25 billion Roundup deal (updated)
U.S. court dismisses appeal over objections to $7.25 billion Roundup deal
Brief: Bayer's Sevabertinib Approved In Japan For Patients With Her2-Mutant Non-Small Cell Lung Cancer
Brief: Bayer Says China's National Medical Products Administration Accepted For Review Application For Aflibercept 8 Mg (114.3 Mg/Ml Solution For Injection)
Bayer's $7.25 billion Roundup deal gets new September court date
Bayer seeks short delay to $7.25 billion Roundup settlement hearing
Media: Bayer seeks to move Roundup settlement hearing to September - Bloomberg News
Bayer's India unit posts quarterly profit rise as expenses shrink